The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms

被引:125
作者
Miller, AL
Chiles, JA
Chiles, JK
Crismon, ML
Rush, AJ
Shon, SP
机构
[1] Department of Psychiatry, Univ. of Texas Hlth. Science Center, 7703 Floyd Curl Dr., San Antonio
关键词
D O I
10.4088/JCP.v60n1002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: In the Texas Medication Algorithm Project (TMAP), detailed guidelines for medication management of schizophrenia and related disorders, bipolar disorders, and major depressive disorders have been developed and implemented. Discussion: This article describes the algorithms developed for medication treatment of schizophrenia and related disorders. The guidelines recommend a sequence of medications and discuss dosing, duration, and switch-over tactics. They also specify response criteria at each stage of the algorithm for both positive and negative symptoms. The rationale and evidence for each aspect of the algorithms are presented.
引用
收藏
页码:649 / 657
页数:9
相关论文
共 55 条
  • [1] ALPHS LD, 1989, PSYCHOPHARMACOL BULL, V25, P159
  • [2] CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES
    ALVIR, JMJ
    LIEBERMAN, JA
    SAFFERMAN, AZ
    SCHWIMMER, JL
    SCHAAF, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) : 162 - 167
  • [3] ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784
  • [4] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
    Arvanitis, LA
    Miller, BG
    Borison, RL
    Pitts, WM
    Sharif, ZA
    Hamner, MB
    Herz, MI
    True, JE
    Velligan, D
    Knesevich, MA
    Small, J
    Steinbook, R
    Hertzman, M
    Keck, PE
    Newcomer, JW
    Grace, J
    Rotrosen, J
    Tandon, R
    Dott, SG
    Ferguson, JM
    Addington, DEN
    MacEwan, GW
    Nair, VNP
    Shriqui, CL
    Williams, R
    Daniel, DG
    Shehi, GM
    Patterson, WM
    Merideth, CH
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (04) : 233 - 246
  • [5] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial
    Beasley, CM
    Tollefson, G
    Tran, P
    Satterlee, W
    Sanger, T
    Hamilton, S
    Fabre, L
    Small, J
    Ereshefsky, L
    True, J
    Nemeroff, C
    Risch, SC
    Perry, PJ
    Potkin, SG
    Borison, RL
    James, S
    Meltzer, HY
    Iqbal, N
    Fann, WE
    Gewirtz, GR
    Landbloom, R
    RoyByrne, PP
    Tuason, VB
    Carman, JS
    Stokes, PE
    Williams, R
    Ancill, RJ
    MacEwan, GW
    Gujavarty, KS
    Jones, B
    Lohr, JB
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 111 - 123
  • [6] BRECHER MB, 1998, 151 ANN M AM PSYCH A
  • [7] BUCHANAN RW, 1990, AM J PSYCHIAT, V147, P290
  • [8] The risk of medication-free research
    Carpenter, WT
    [J]. SCHIZOPHRENIA BULLETIN, 1997, 23 (01) : 11 - 18
  • [9] CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578
  • [10] CONLEY RR, 1998, 11 EUR COLL NEUR C O